Skip to content
Companies

Montara Therapeutics

Brain-targeted drugs for neurological disease

Raised to date

$20M

of $20M offered across 1 Form D filing

Investors
9
Last filed
Mar 13, 2025

About

Montara Therapeutics, Inc. is a preclinical-stage biopharmaceutical company dedicated to the development of innovative therapies for neurological diseases and brain cancers. With a strong emphasis on minimizing peripheral side effects and enhancing the efficacy of treatments, Montara is at the forefront of addressing critical challenges in the neurological therapeutics space.

Montara stands out with its BrainOnly™ platform, which enables targeted brain-specific drug activity while effectively mitigating adverse peripheral effects.

Funding

  • EquityFiled Mar 13, 2025Form D
    $20M/ $20M

Product

BrainOnly™ Platform

Therapeutic Platform

The BrainOnly™ platform is Montara's core technology designed to facilitate brain-specific drug activity. It enables the development of therapies that selectively target neurological conditions while avoiding the toxicities typically associated with systemic treatments.

  • Supports two-drug combination therapies with a brain-penetrant drug and a non-brain penetrant peripheral blocker.
  • Enhances the safety and efficacy profile of existing neurological drugs.
  • Enables the targeting of previously considered 'undruggable' pathways related to brain diseases.

Built for

Patients with neurological disorders

People on file